These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16410650)

  • 21. The peptidomics concept.
    Schulz-Knappe P; Schrader M; Zucht HD
    Comb Chem High Throughput Screen; 2005 Dec; 8(8):697-704. PubMed ID: 16464157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ultrasound Shear Wave Elastography for Liver Disease. A Critical Appraisal of the Many Actors on the Stage.
    Piscaglia F; Salvatore V; Mulazzani L; Cantisani V; Schiavone C
    Ultraschall Med; 2016 Feb; 37(1):1-5. PubMed ID: 26871407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical neuroproteomics and biomarkers: from basic research to clinical decision making.
    Shoemaker LD; Achrol AS; Sethu P; Steinberg GK; Chang SD
    Neurosurgery; 2012 Mar; 70(3):518-25. PubMed ID: 21866062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical mass spectrometry in neuroscience. Proteomics and peptidomics.
    Davidsson P; Brinkmalm A; Karlsson G; Persson R; Lindbjer M; Puchades M; Folkesson S; Paulson L; Dahl A; Rymo L; Silberring J; Ekman R; Blennow K
    Cell Mol Biol (Noisy-le-grand); 2003 Jul; 49(5):681-8. PubMed ID: 14528905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and development of biomarkers of neurological disease.
    Dunckley T; Coon KD; Stephan DA
    Drug Discov Today; 2005 Mar; 10(5):326-34. PubMed ID: 15749281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.
    Kroksveen AC; Opsahl JA; Aye TT; Ulvik RJ; Berven FS
    J Proteomics; 2011 Apr; 74(4):371-88. PubMed ID: 21111852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective.
    Alvarez-Llamas G; de la Cuesta F; Barderas ME; Darde V; Padial LR; Vivanco F
    Expert Rev Proteomics; 2008 Oct; 5(5):679-91. PubMed ID: 18937558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical application of urinary proteomics/peptidomics.
    Albalat A; Mischak H; Mullen W
    Expert Rev Proteomics; 2011 Oct; 8(5):615-29. PubMed ID: 21999832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptides as "better biomarkers"? Value, challenges, and potential solutions to facilitate implementation.
    Latosinska A; Frantzi M; Siwy J
    Mass Spectrom Rev; 2024; 43(6):1195-1236. PubMed ID: 37357849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of cerebrospinal fluid in biomarker studies.
    Teunissen CE; Verheul C; Willemse EAJ
    Handb Clin Neurol; 2017; 146():3-20. PubMed ID: 29110777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization for Peptide Sample Preparation for Urine Peptidomics.
    Sigdel TK; Nicora CD; Qian WJ; Sarwal MM
    Methods Mol Biol; 2018; 1788():63-72. PubMed ID: 29623538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display.
    Tammen H; Schulte I; Hess R; Menzel C; Kellmann M; Mohring T; Schulz-Knappe P
    Proteomics; 2005 Aug; 5(13):3414-22. PubMed ID: 16038021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptidomics analysis of lymphoblastoid cell lines.
    Fogli A; Bulet P
    Methods Mol Biol; 2010; 615():247-57. PubMed ID: 20013214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simple quantitation for potential serum disease biomarker peptides, primarily identified by a peptidomics approach in the serum with hypertensive disorders of pregnancy.
    Hamamura K; Nonaka D; Ishikawa H; Banzai M; Yanagida M; Nojima M; Yoshida K; Lee LJ; Tanaka K; Takamori K; Takeda S; Araki Y
    Ann Clin Biochem; 2016 Jan; 53(Pt 1):85-96. PubMed ID: 25838414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developing an integrated proteo-genomic approach for the characterisation of biomarkers for the identification of Bacillus anthracis.
    Misra RV; Ahmod NZ; Parker R; Fang M; Shah H; Gharbia S
    J Microbiol Methods; 2012 Feb; 88(2):237-47. PubMed ID: 22178189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ensembles of protein termini and specific proteolytic signatures as candidate biomarkers of disease.
    Huesgen PF; Lange PF; Overall CM
    Proteomics Clin Appl; 2014 Jun; 8(5-6):338-50. PubMed ID: 24497460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of Proteomics in Clinical Trials.
    He T
    Proteomics Clin Appl; 2019 Mar; 13(2):e1800198. PubMed ID: 30702805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarker discovery and applications for foods and beverages: proteomics to nanoproteomics.
    Agrawal GK; Timperio AM; Zolla L; Bansal V; Shukla R; Rakwal R
    J Proteomics; 2013 Nov; 93():74-92. PubMed ID: 23619387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
    Smith JG; Gerszten RE
    Circulation; 2017 Apr; 135(17):1651-1664. PubMed ID: 28438806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.